Dual-Action Antiviral Treatments Offer A New Path Forward

Dual‑action antibody fragments that trigger and then block alphavirus entry protected against lethal equine encephalitis and ...
MarketWatch

Montis Biosciences Advances First-in-Class Dual-Action C1q Antibody with Strong Preclinical Proof-of-Concept in Neuroinflammatory Diseases

The MarketWatch News Department was not involved in the creation of this content. -- Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated ...
The American Journal of Managed Care

The Rise of Precision Monoclonal Antibodies in Treating MS

B-cell depletion is effective in MS and NMOSD, with anti-CD20 and anti-CD19 mAbs showing distinct mechanisms impacting safety and tolerability. Glycoengineering enhances ADCC activity, mitigating ...
ascopubs.org

Bispecific Antibodies in Non–Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration

Both agents, and those on the horizon, have unique toxicities based on their antibody construct, mechanism of action, or related on-target side effects. In this study, we review the therapeutic ...

Immutrin raises £65 million ($87 million) Series A to develop next generation antibody therapy for ATTR amyloidosis

Oversubscribed financing led by Frazier Life Sciences with participation from F-Prime, Qiming Venture Partners, SR One and founding investors ...
Business Insider

Montis Biosciences Advances First-in-Class Dual-Action C1q Antibody with Strong Preclinical Proof-of-Concept in Neuroinflammatory Diseases

Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammation MB0109 demonstrated ...